SCHEMBL14587249

SCHEMBL14587249

CCCCCCCC/C=C/CCCCCCCCN(CCCCN(CCCCCCCC/C=C/CCCCCCCC)CC(O)CN)CC(O)CN

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
FAAH O00519 4/20 0.42
TP53 P04637 2/20 0.42
CYP1A2 P05177 2/20 0.42
CYP2C19 P33261 2/20 0.42
CYP3A4 P08684 2/20 0.42
SOAT1 P35610 2/20 0.42
MAPT P10636 3/20 0.41
GMNN O75496 2/20 0.41
LMNA P02545 2/20 0.41
GLA P06280 2/20 0.41
POLB P06746 2/20 0.41
THRB P10828 2/20 0.41
CETP P11597 2/20 0.41
MAPK1 P28482 2/20 0.41
CXCR5 P32302 2/20 0.41
CCR6 P51684 2/20 0.41
BLM P54132 2/20 0.41
UBE2N P61088 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14288365 1.00 MEN1 (0.42) MEN1KMT2AFAAHTP53CYP1A2
SCHEMBL13991599 1.00 MEN1 (0.42) MEN1KMT2AFAAHTP53CYP1A2
SCHEMBL721174 0.97 MEN1 (0.42) MEN1KMT2AFAAHTP53CYP1A2
SCHEMBL721173 0.97 MEN1 (0.42) MEN1KMT2AFAAHTP53CYP1A2
SCHEMBL26835765 0.95 KDM4E (0.46) CYP3A4SOAT1LMNAALDH1A1ALOX15
SCHEMBL26858557 0.95 KDM4E (0.46) CYP3A4SOAT1LMNAALDH1A1ALOX15
SCHEMBL26835758 0.95 KDM4E (0.46) CYP3A4SOAT1LMNAALDH1A1ALOX15
SCHEMBL26835759 0.95 KDM4E (0.46) CYP3A4SOAT1LMNAALDH1A1ALOX15
SCHEMBL31285101 0.95 KDM4E (0.46) CYP3A4SOAT1LMNAALDH1A1ALOX15
SCHEMBL26835769 0.94 KDM4E (0.45) CYP3A4SOAT1LMNAALDH1A1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223886-B1 COMPOSITIONS AND METHODS FOR THE STABILIZATION OF MICRO-RNA GENFIT (FR) 2024-10-02 EP disclosed
EP-4223886-A2 COMPOSITIONS AND METHODS FOR THE STABILIZATION OF MICRO-RNA Genfit (FR) 2023-08-09 EP disclosed
US-20220186313-A1 COMPOSITIONS AND METHODS FOR THE STABILIZATION OF MICRO-RNA GENFIT (FR) 2022-06-16 US disclosed
US-9358300-B2 Transfection reagents Life Technologies Corporation (US) 2016-06-07 US disclosed
US-20150190522-A1 TRANSFECTION REAGENTS LIFE TECHNOLOGIES CORP (US) 2015-07-09 US disclosed
US-8785200-B2 Transfection reagents Life Technologies Corporation (US) 2014-07-22 US disclosed
US-7173154-B2 Transfection reagents INVITROGEN CORP. (US) 2007-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150190522-A1 TRANSFECTION REAGENTS CPS1, PHAX, HNRNPH3 MEN1 2562/4885KMT2A 1358/4885FAAH 4753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.